** Shares of telehealth firm Hims & Hers Health HIMS.N fall 6.61% to $39.11 premarket
** Co sees Q2 revenue to be between $530 million and $550 million, below estimates of $564.6 million - data compiled by LSEG
** HIMS expects onetime quarter-over-quarter revenue drop in Q2, as it transitions subscribers previously on commercially available dosages of Novo Nordisk's NOVOb.CO semaglutide to options on its or other platforms by end of quarter
** Reaffirms full-year revenue forecast of $2.3 billion to $2.4 billion
** We suspect that the re-affirmed 2025 and new Q2 forecast is likely "conservative," brokerage BTIG says
** Q1 revenue of $586.0 million beats estimates of $538.2 million
** Up to last close, stock up ~73% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。